What does it do?
FIGS is a growth business that earns money by selling high-end medical uniforms and lifestyle apparel directly to healthcare professionals through its website and app. By cutting out traditional retail stores, the company captures the full markup on its products and maintains a direct relationship with its customers. The core product is its proprietary fabric blend that offers stretch and moisture-wicking properties, marketed as a professional upgrade from the baggy, uncomfortable scrubs historically sold in hospital gift shops. Healthcare workers pay a premium for style and function, which creates a recurring revenue stream as they replace worn-out uniforms every few months.
Where does revenue come from?
The vast majority of revenue comes from scrubwear, which accounts for over 80% of total sales. The company is diversifying its mix with non-scrub items like lab coats, compression socks, and footwear making up roughly 18% of revenue. Geographically, the United States remains the primary market at 80% of sales, though international revenue is growing at a much faster 67% rate as the brand launches in new countries.
Revenue Breakdown
Revenue by Geography
Who are its customers?
FIGS serves 3.1 million active customers who primarily consist of nurses, doctors, and other medical professionals. The company tracks its base by counting unique accounts that have made a purchase in the last 12 months, with this number growing 13.2% over the last year. These customers spend an average of $127 per order, an 8.5% increase from the prior year, and generate $229 in net revenue per customer annually. Engagement is high, as purchase frequency recently surpassed pandemic-era peaks, signaling that the brand is becoming a permanent fixture in the healthcare professional's daily wardrobe.
What gives it staying power?
FIGS has staying power through its strong brand identity and a direct-to-consumer model that builds community through its "Ambassador" program. This creates high brand loyalty in an industry where scrubs were previously treated as generic commodities. While competitors can copy fabric, they struggle to replicate the emotional connection FIGS has established with healthcare workers.
Where is it headed?
The company is making a major strategic bet on becoming a full-wardrobe solution for healthcare workers, expanding into footwear and out-of-hospital apparel. Management believes they can capture a larger share of the "around-the-clock" lifestyle of their 3.1 million customers. If successful, this moves FIGS from being a uniform company to a broader healthcare lifestyle brand, significantly increasing the total amount each customer spends over their career.
Revenue growth has accelerated to 28.8% year-over-year, reaching $196.6 million as international and new product segments surge. This growth is a sharp reversal from the slower trends seen in 2024 and shows the brand is successfully expanding its reach. The acceleration is particularly meaningful because it was driven by both more customers and higher spending per order.
Free cash flow is exceptionally strong at $38.6 million for the first half of 2026, tracking well ahead of net income. The company generates cash efficiently because it carries no debt and has optimized its inventory levels, which fell to $119.6 million from $128.0 million last year. This cash generation allows for aggressive share repurchases and reinvestment without external funding.
The balance sheet is a fortress with $296 million in cash and short-term investments and no traditional bank debt. With a tiny debt-to-equity ratio of 0.13x, FIGS has the financial flexibility to weather economic downturns or fund large-scale international marketing. This massive cash pile represents nearly 15% of the company's total market value.
FIGS is a financially disciplined growth business that is successfully pairing high revenue growth with expanding profit margins.
The international business is the clear standout, growing 67% year-over-year to reach $37.9 million in quarterly revenue. This proves the FIGS brand resonates globally and provides a massive secondary runway as the U.S. market matures. By utilizing the same direct-to-consumer playbook abroad, the company is seeing rapid adoption without the need for physical stores.
Tariffs and sourcing costs remain the primary threat to FIGS' high gross margins. While margins hit 75.2% this quarter, this was aided by a one-time $7.9 million tariff refund, and underlying costs could rise if trade policies become more restrictive. Management is trying to diversify its manufacturing away from high-tariff regions, but a sudden shift in global trade could squeeze profits.
The healthcare apparel market is roughly $85 billion globally today, growing about 6% annually, and is on track to exceed $110 billion by 2030. Pricing power is structural for premium brands because healthcare professionals view scrubs as essential tools of the trade rather than discretionary fashion. FIGS is the clear leader in the premium direct-to-consumer niche, enjoying a massive growth runway as it converts traditional scrub buyers into its higher-margin ecosystem.
The market is increasingly competitive as legacy uniform brands launch their own high-stretch, fashion-forward lines to defend their share. Barriers to entry are low for basic apparel, but building a brand that professionals will pay double for is difficult. Pricing power is the primary battleground as rivals use discounts to attract price-sensitive nurses.
Dickies Medical and Cherokee Uniforms are the primary threats because they own the institutional and wholesale channels that FIGS avoids. These companies can bundle products and offer bulk discounts to hospitals that FIGS' direct model cannot easily match. The most dangerous threat is a legacy brand successfully launching a premium direct-to-consumer sub-brand at a 20% lower price point.
FIGS is currently gaining share as its 28.8% revenue growth far outpaces the broader industry's single-digit growth. The company is successfully out-executing rivals by focusing on customer experience rather than just the garment.
The primary source of protection is an intangible asset: the FIGS brand and its direct relationship with 3.1 million healthcare professionals. This brand power allows FIGS to charge $80 or more for a set of scrubs that costs far less to manufacture. Customers view FIGS as a badge of professional status, which acts as a powerful barrier to competitors.
The 75.2% gross margins and 11% ROIC prove that FIGS has a genuine edge over commodity apparel makers. Retention is visible in the net revenue per active customer, which recently hit an all-time high of $229. These numbers confirm that customers are not just buying once but are building their entire professional wardrobe around the brand.
The Narrow rating reflects that while the brand is strong, there are no structural switching costs to prevent a nurse from buying a different brand tomorrow. Scrubs are fundamentally a replaceable garment, which limits the moat from being Wide.
The moat is strengthening as the company expands into footwear and international markets. Record high revenue per active customer is the clearest signal that the brand's competitive advantage is growing deeper.
Three straight quarters of 25%+ revenue growth and repeated guidance raises.
$100M increase to buyback program and $296M in cash with no debt.
Founders Catherine Spear and Heather Hasson maintain significant ownership and control of the company.
Capital Allocation Track Record
Catherine Spear has demonstrated exceptional judgment by successfully navigating the post-pandemic slowdown and re-accelerating the business through category expansion. Management has been highly disciplined with the balance sheet, maintaining a $296 million cash pile while funding growth entirely through operations. Their ability to grow active customers to 3.1 million while simultaneously raising prices and expanding margins shows a rare combination of brand-building and operational skill.
The primary governance risk is the high level of control held by the founders, though this is mitigated by their clear alignment with long-term shareholders. As co-founders, Spear and Hasson are the driving force behind the company's culture and brand vision, making them key-person risks if either were to leave. However, the company has built a deep bench of executives, including CFO Sarah Oughtred, who have been instrumental in the recent operational turn.
We expect revenue to grow from $0.7B in FY2026 to $1.2B in FY2031 (~10% CAGR), with EPS growing from $0.26 to $0.59 (~18% CAGR). International expansion and new product categories like footwear are broadening the brand's reach beyond basic medical scrubs. Marketing and shipping costs are spread over a larger, more loyal customer base, allowing more profit to be retained from each sale. EPS grows faster than revenue because profit margins are widening as the company scales its operations. Operating margin expected to reach ~15% by FY2031.
International markets become a primary engine for total company growth. If international revenue maintains its 60%+ growth rate, it will soon represent a major share of total profits and offset U.S. maturity.
Footwear and outerwear categories double the total customer lifetime value. Expanding into the full wardrobe of healthcare professionals allows FIGS to capture more spending without needing to find new customers.
TEAMS platform gains traction with large healthcare institutions for uniforming. If large hospitals shift to FIGS as their official uniform partner, it creates a massive, recurring, and predictable B2B revenue stream.
Souring trade relations and new tariffs squeeze high gross margins. Higher costs on imported fabrics or finished goods could force FIGS to raise prices further, potentially alienating its core customer base.
Marketing costs rise as competition for healthcare professionals intensifies. If rivals spend aggressively to win back customers, FIGS may see its marketing efficiency drop, hurting net income despite revenue growth.
A recession causes healthcare workers to delay non-essential scrub replacements. While healthcare is stable, premium scrubs are a discretionary upgrade that could be delayed if consumer confidence and spending take a hit.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Normalized P/E approach based on mid-cycle earnings power rather than the current peak print. It fits FIGS because the business recently saw a massive jump in profit margins (17.9%) that likely reflects a temporary peak; using a smoothed, "normalized" profit level prevents us from overvaluing the stock based on a single outlier quarter.
Our mid-cycle earnings estimate of $0.38 per share multiplied by a 35x multiple gives a per-share fair value of $13.30. A 35x P/E (price-to-earnings ratio) sits at the high end of the apparel peer range of 22-38x (Lululemon at 28x, On Holding at 35x), which is justified by FIGS' best-in-class 68.4% gross margins and superior 28% growth rate. We use the projected FY2028 earnings of $0.38 from the deterministic engine as our "normalized" base, as this represents the company's earning power once recent expansion costs and margin spikes have settled.
A cross-check using mid-cycle EV/EBITDA produces a fair value of $11—within 18% of our primary result and confirming the valuation range. We arrived at this by applying a 15x multiple—the average for high-growth consumer brands—to a normalized yearly cash profit (EBITDA) of $102 million. This yields a total company value of roughly $1.75 billion after adding back the company's $216 million in cash. While this is slightly lower than our primary $13 target, the two methods are close enough to suggest the current $11.24 market price is a fair reflection of the company's steady-state value.
We're assuming FIGS maintains revenue growth between 14% and 16% through FY2027. This matches management’s recent guidance and is supported by the 28% growth seen in the most recent quarter, which was driven by a record 3 million active customers and higher spending per person.
We're assuming operating margins stabilize near 14% over the long term. While the company recently hit a peak of nearly 18% in the latest quarter, historical levels have been much lower; a mid-teen margin reflects a balance between the current efficiency and the costs needed to expand globally.
We're assuming the "lifestyle" segment—items like jackets and bags—continues to grow faster than core scrubs. Non-scrub wear currently makes up about 19% of sales, and its continued success is vital for FIGS to be valued as a diversified apparel brand rather than just a uniform manufacturer.
The biggest risk is that international expansion or new product lines fail to gain traction, leaving the company trapped in the limited US scrub market. This would likely pull the valuation multiple from 35x down to 18x, knocking roughly $6 off the per-share fair value as growth investors exit. Watch for any stagnation in "active customer" growth or a reversal in the recently improved 17.9% operating margins.
Bear case ($8): Active customer growth slows below 8% for two consecutive quarters, suggesting the brand has hit a ceiling in the US medical community; or Operating margins drop back toward 5% as rising freight costs and heavy promotions to clear non-scrub inventory eat into profits.
Bull case ($19): International revenue growth accelerates above 40% year-over-year, proving the brand translates across global healthcare markets; or Lifestyle and non-scrub products reach 25% of the total sales mix, transforming FIGS into a broader apparel compounder.
Clearthesis wrote this report from 46 sources, including SEC filings, analyst estimates, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on August 7, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.